Wed, May 12, 2010
[ Wed, May 12th 2010 ]: Market Wire
ENVIROTEK Becomes "SUFFER"
Tue, May 11, 2010
Mon, May 10, 2010
Sun, May 9, 2010
Sat, May 8, 2010
Fri, May 7, 2010
Thu, May 6, 2010
Mon, January 11, 2010
Sat, January 9, 2010
Fri, January 8, 2010
Thu, January 7, 2010
Wed, January 6, 2010
Tue, January 5, 2010
Mon, January 4, 2010
[ Mon, Jan 04th 2010 ]: Market Wire
Cordani Becomes CIGNA CEO
Thu, December 31, 2009
[ Thu, Dec 31st 2009 ]: Market Wire
Quit the Board
Wed, December 30, 2009
[ Wed, Dec 30th 2009 ]: Market Wire
Centric Grants Stock Options
Tue, December 29, 2009
Mon, December 28, 2009
Thu, December 24, 2009

MedaSorb Technologies Announces Company Name Change to CytoSorbents Corporation


  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. any-name-change-to-cytosorbents-corporation.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

MONMOUTH JUNCTION, NJ--(Marketwire - May 6, 2010) - MedaSorb Technologies Corporation, formerly trading under the symbol (OTCBB: [ MSBT ]), has formally changed its company name to CytoSorbents Corporation. Pursuant to the name change, effective at the open of business on May 7, 2010, the new ticker symbol for the Company will be (OTCBB: [ CTSO ]).

For additional information on the Company, please see our Form 10-K filed with the SEC on April 9, 2010 under our former name MedaSorb Technologies Corporation, which is available at [ www.sec.gov ].

About CytoSorbents and CytoSorb™

CytoSorbents Corporation, and its operating subsidiary CytoSorbents, Inc., is a therapeutic device company in clinical trials to treat severe sepsis, often called "overwhelming infection," with a novel blood purification device called CytoSorb™. Severe sepsis afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. However, it is the body's abnormal immune response to the trigger that leads to the unregulated, massive production of cytokines, often called "cytokine storm," that then causes severe inflammation, organ failure and often death.. CytoSorb™ is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped through the CytoSorb™ cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial -- a multi-center, randomized, controlled clinical trial using CytoSorb™ to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb™ in the European Union. CytoSorb™ is one of a number of different resins designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, treatment of rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the Company's website: [ www.cytosorbents.com ]

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-K filed with the SEC on April 9, 2010, which is available at [ http://www.sec.gov ].


Publication Contributing Sources